WallStreetZenWallStreetZen

NASDAQ: MDCX
Medicus Pharma Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their MDCX stock forecasts and price targets.

Forecast return on equity

Is MDCX forecast to generate an efficient return?

Company
-2,667.44%
Industry
7.99%
Market
180.2%
MDCX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is MDCX forecast to generate an efficient return on assets?

Company
173.49%
Industry
27.18%
MDCX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

MDCX earnings per share forecast

What is MDCX's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$34.17
Avg 2 year Forecast
-$18.74
Avg 3 year Forecast
-$17.34

MDCX revenue forecast

What is MDCX's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

MDCX vs General Drug Manufacturer Stocks

TickerPricePrice TargetUp/downsideConsensus
MDCX$2.62N/AN/A
SCLX$2.47N/AN/A
MIRA$0.63$3.50+456.44%Strong Buy
NSRX$3.23N/AN/A
AMRN$11.60$13.00+12.07%Strong Sell
View Top General Drug Manufacturer Stocks

Medicus Pharma Stock Forecast FAQ

What is MDCX's earnings growth forecast for 2026-2028?

(NASDAQ: MDCX) Medicus Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - General industry's average forecast earnings growth rate of 39.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.78%.

Medicus Pharma's earnings in 2026 is -$56,663,183.On average, 6 Wall Street analysts forecast MDCX's earnings for 2026 to be -$43,177,622, with the lowest MDCX earnings forecast at -$48,295,251, and the highest MDCX earnings forecast at -$33,833,211. On average, 6 Wall Street analysts forecast MDCX's earnings for 2027 to be -$23,683,248, with the lowest MDCX earnings forecast at -$36,531,023, and the highest MDCX earnings forecast at -$5,307,170.

In 2028, MDCX is forecast to generate -$21,911,032 in earnings, with the lowest earnings forecast at -$33,435,174 and the highest earnings forecast at -$9,287,548.

If you're new to stock investing, here's how to buy Medicus Pharma stock.

What is MDCX's revenue growth forecast for 2026-2028?

(NASDAQ: MDCX) Medicus Pharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 7.49%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.2%.

Medicus Pharma's revenue in 2026 is $0.On average, 6 Wall Street analysts forecast MDCX's revenue for 2026 to be $0, with the lowest MDCX revenue forecast at $0, and the highest MDCX revenue forecast at $0. On average, 6 Wall Street analysts forecast MDCX's revenue for 2027 to be $0, with the lowest MDCX revenue forecast at $0, and the highest MDCX revenue forecast at $0.

In 2028, MDCX is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is MDCX's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: MDCX) forecast ROA is 173.49%, which is higher than the forecast US Drug Manufacturers - General industry average of 27.18%.

What is MDCX's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: MDCX) Medicus Pharma's current Earnings Per Share (EPS) is -$123.00. On average, analysts forecast that MDCX's EPS will be -$34.17 for 2026, with the lowest EPS forecast at -$38.22, and the highest EPS forecast at -$26.78. On average, analysts forecast that MDCX's EPS will be -$18.74 for 2027, with the lowest EPS forecast at -$28.91, and the highest EPS forecast at -$4.20. In 2028, MDCX's EPS is forecast to hit -$17.34 (min: -$26.46, max: -$7.35).

What is MDCX's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: MDCX) forecast ROE is -2,667.44%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.